---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036777"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-08-10T13:45:14+00:00"
generated_at: "2026-08-10T13:46:07.540299+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma completes $30M acquisition of Dura Driver Control Systems

## Summary
- Acquired 100% of DCS for ~$30.0M cash; DCS becomes wholly owned subsidiary on Aug 6, 2026.
- DCS FY2025 revenue $209.5M and Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.
- Entered $22.5M senior secured revolving credit facility to fund acquisition, along with cash on hand.
- Issued $3.75M convertible notes for $3.0M (20% OID), conversion at $8.00/share for working capital.
- DCS CEO Hans Vorstenbosch stays; 11 plants, 310+ patents, 50+ customers, top-10 OEM avg 28-yr relationship.

## SEC filing metadata
- accession: 0001493152-26-036777
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-08-10T13:45:14+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/0001493152-26-036777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036777
- JSON: https://secwatch.observer/filing/0001493152-26-036777.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.